All In Biotech

Drug Trial Radar · NCT03655613

APL-501 or Nivolumab in Combination With APL-101 in Locally Advanced or Metastatic HCC and RCC

A Phase 1/2 Dose Escalation and Expansion Study of Combination APL-501 or Nivolumab With APL-101 in Locally Advanced or Metastatic Hepatocellular and Renal Cell Carcinoma

Last checked: Nov 19, 2026Latest source record: May 6, 2022 (this record)Source: ClinicalTrials.govMethods & limitations

Terminated

Status

Terminated

Enrollment

20

Actual

Start

Sep 5, 2018

Primary completion

Dec 15, 2021

Study completion Dec 15, 2021

Sponsor

Sponsor type
Industry
Collaborators
Apollomics Inc. (formerly CBT Pharmaceuticals, Inc.); Novotech (Australia) Pty Limited
First posted
Aug 31, 2018

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Study Design and Investigational Plan: This is an open-label Phase 1/2 study to assess the safety and tolerability of combination PD-1 inhibitor (APL-501 or nivolumab) administered concomitantly with c-Met inhibitor (APL-101), to determine the recommended Phase 2 dose of the combination, and to obtain preliminary efficacy in HCC or RCC subjects with advanced or metastatic disease that have not been previously treated with a PD 1 inhibitor or a c-Met inhibitor. HCC subjects will receive the combination APL-501 plus APL-101 while RCC subjects will receive the combination nivolumab plus APL-101. In Phase 1, mandatory archival or fresh tumor biopsies will be collected. In Phase 2, a mandatory fresh tumor biopsy will be required for study entry and another fresh biopsy will be collected between Cycles 2 and 4. The frequency of administration of PD-1 inhibitors will be every 2 weeks starting in Cycle 1 on Day 8 and Day 22 of a 35-day cycle with all subsequent cycles on Day 1 and Day 15 of 28-day cycles. APL-101 will be administered orally every 12 hours continuously on an empty stomach.

Conditions

  • Hepatocellular Carcinoma
  • Renal Cell Carcinoma

Interventions

  • APL-501Biological

    Humanized IgG4 monoclonal antibody against programmed death receptor-1 (PD-1)

  • APL-101Drug

    Oral specific c-Met inhibitor

  • NivolumabBiological

    Fully human IgG4 monoclonal antibody against PD-1

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Dose Limiting Toxicities (Phase 1)Time frame: Cycle 1 (up to 35 days)

Locations

9 sites in 2 countries. Site status is shown where the registry gives one.

  • Border Medical Oncology Research Unit

    Albury, New South Wales, Australia

  • Macquarie University

    Sydney, New South Wales, Australia

  • Crown Princess Mary Cancer Centre

    Westmead, New South Whales, Australia

  • Ashford Cancer Center

    Adelaide, South Australia, Australia

  • Royal Melbourne Hospital

    Melbourne, Victoria, Australia

  • Sunshine Hospital

    Saint Albans, Victoria, Australia

  • Fiona Stanley Hospital

    Murdoch, Western Australia, Australia

  • Afffinity Clinical Research

    Perth, Western Australia, Australia

  • Auckland City Hospital

    Auckland, New Zealand

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.